Garry Menzel joins GHO Capital as Operating Partner
23 Abril 2024 - 1:00AM
Garry Menzel joins GHO Capital as Operating Partner
Garry Menzel joins GHO Capital as
Operating Partner
Former CEO of TCR² Therapeutics with
significant investment and operating experience to support deal
origination and provide best in class services to pioneering
healthcare companies
London, UK – 23 April 2024:
Global Healthcare Opportunities, or GHO Capital Partners LLP
(“GHO”), the European specialist investor in global healthcare, is
pleased to announce the appointment of Dr. Garry Menzel as
Operating Partner.
Garry brings a unique blend of scientific,
strategic, investment and operating skills with diverse experiences
from more than 25 years of building healthcare businesses and
leading high-performing teams. Most recently he was President and
Chief Executive Officer of immunotherapy company TCR² Therapeutics,
leading it from concept to clinical trial success before its merger
with Adaptimmune (Nasdaq: ADAP) in March 2023 where he became a
member of the Board.
Prior to TCR² Therapeutics, Garry was the Chief
Financial Officer of DaVita Healthcare Partners (NYSE:DVA),
providing kidney dialysis and primary care physician services, and
later became a founding Board member of Black Diamond Therapeutics
(Nasdaq:BDTX), a clinical stage precision oncology company. Garry
is also a Board member of Stoke Therapeutics (Nasdaq:STOK), a
clinical stage biotechnology company using novel antisense
oligonucleotide medicines to treat severe genetic diseases.
In addition to his operating roles, Garry has
held executive leadership roles in global investment banking at
Goldman Sachs, where he founded its biotechnology franchise while
also supporting numerous medical device and hospital groups, and as
Head of Global Life Sciences at Credit Suisse. In these positions,
he advised on financial transactions worth more than $100 billion.
He was also a consultant with Bain where he worked with companies
from various industries to develop and implement strategies that
create long-term value. Garry holds a Ph.D. in Biochemistry and
Molecular Biology from the University of Cambridge and an M.B.A
from Stanford University.
As Operating Partner, Garry will leverage his
extensive biotech industry experience in building innovative
businesses to guide the GHO portfolio to deliver market leading
services to the emerging biopharma space, as well as supporting GHO
with deal origination across Europe and the US.
The Partners at GHO Capital
commented: “Garry’s commitment to building companies
focused on developing new technologies that deliver better
medicines and services for patients, closely aligns with GHO’s core
principles. His combination of scientific, strategic, investment,
and operating experience in healthcare will support our work with
innovative companies, strengthening our ability to guide our
portfolio companies towards building the next generation of
healthcare solutions. On behalf of the entire GHO team, we wish him
a warm welcome.”
Commenting on his new appointment, Garry
Menzel, Operating Partner at GHO Capital, said:
“Throughout my career, I have been committed to bringing forward
the highest possible innovative standards for patients within the
healthcare system whilst creating long-term investor value. I am
excited to support GHO Capital, as Europe’s leading healthcare
specialist private equity firm, to pursue the same goal. Their
relentless focus on achieving better, faster and more accessible
healthcare is a central ethos that we share. I look forward to
working with their incredible portfolio companies and experienced
specialist team to shape the future of healthcare.”
-Ends-
Further information:
GHO Capital Partners LLP
T +44 20 3700 7440
E IR@ghocapital.com
For Media
EnquiriesICR Consilium Amber Fennell,
Angela Gray |
Tel: +44 (0) 20 3709 5700ghocapital@consilium-comms.com |
About GHO Capital
Global Healthcare Opportunities, or GHO Capital
Partners LLP, is a leading specialist healthcare investment advisor
based in London. We apply global capabilities and perspectives to
unlock high growth healthcare opportunities, targeting Pan-European
and transatlantic internationalisation to build market leading
businesses of strategic global value. Our proven investment track
record reflects the unrivalled depth of our industry expertise and
network. We partner with strong management teams to generate
long-term sustainable value, improving the efficiency of healthcare
delivery to enable better, faster, more accessible healthcare. For
further information, please visit www.ghocapital.com.